When was Akari Therapeutics founded?

Akari Therapeutics was founded in 2005 and raised its 1st funding round 7 years after it was founded.

Where is Akari Therapeutics located?

Akari Therapeutics is headquartered in New York City, United States. It is registered at HIGHDOWN HOUSE,YEOMAN WAY,WORTHING,WEST SUSSEX,UNITED KINGDOM,BN99 3HH.

How many employees does Akari Therapeutics have?

As of Aug 31, 2026, the latest employee count at Akari Therapeutics is 15.

Is Akari Therapeutics a funded company?

Akari Therapeutics is a funded company, having raised a total of $2.43M across 10 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 13, 2012.

When was the latest funding round of Akari Therapeutics?

Akari Therapeutics' latest funding was a $***** Post IPO round on Dec 16, 2025, with participation from 0 investor.

Where does Akari Therapeutics rank among its competitors?

Akari Therapeutics ranks 73rd amongst 546 active competitors, of which 181 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Akari Therapeutics, which secured an undisclosed amount in Dec, 2025.

Who are the top competitors of Akari Therapeutics?

Akari Therapeutics' top competitors include Biogen, Abcellera Biologics and Sana Biotechnology. Among them, Akari Therapeutics secured the most recent funding round in December, 2025.

Akari Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. Its lead candidate is Nomacopan is being evaluated for four therapeutic areas which include bullous pemphigoid (BP), a severe blistering skin disease, thrombotic microangiopathy, AMD, and asthma. It is also developed compounds that inhibit the leukotriene system such as thromboxane A2.

Website: akaritx.com
Social
Registered Address: HIGHDOWN HOUSE,YEOMAN WAY,WORTHING,WEST SUSSEX,UNITED KINGDOM,BN99 3HH

Key Metrics

Founded Year

2005

Location

New York City, United States

Stage

Public

Total Funding

$2.43M in 10 rounds

Latest Funding Round

Post IPO, Dec 16, 2025, $*****

Investors

Foresite Capital & 8 more

Ranked

73^rd among 546 active competitors

Employee Count

15 as on Aug 31, 2026

Similar Companies

Biogen & 648 more

Exit Details

Public

View Akari Therapeutics' full profile

Akari Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
AKARI THERAPEUTICS, PLC CIN: 4205807 , United States, Active	Feb 22, 2012	-	-	-
AKARI THERAPEUTICS PLC CIN: 1541157 , United States, Active		-	5 (As on Dec 31, 2014)	-
AKARI THERAPEUTICS, PLC CIN: 5252842 , United Kingdom, Active	Oct 06, 2004	-	-

Akari Therapeutics got listed on Sep 28, 2015.

Click here to take a look at Akari Therapeutics's IPO in detail

Akari Therapeutics has raised a total funding of $2.43M over 10 rounds. Its first funding round was on Dec 13, 2012. Akari Therapeutics has 8 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Akari Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 16, 2025	8736122	Post IPO	8893326	8071098	7716938	4145757
Mar 03, 2025	3408603	Post IPO	7967526	9526049	1245037	3208991
Dec 29, 2023	8456883	Post IPO	9581429	3654209	5566116	Samir Patel

Access funding benchmarks and valuations. Sign up today!

View details of Akari Therapeutics's funding rounds and investors

Akari Therapeutics' employee count trend

Akari Therapeutics has 15 employees as of Aug 26. Here is Akari Therapeutics's employee count trend over the years:

Employee count trend for Akari Therapeutics

Uncover Akari Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Akari Therapeutics include Biogen, Abcellera Biologics and Sana Biotechnology. Here is the list of Top 10 competitors of Akari Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	Woodford Investment Management, General Atlantic ... & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Apax & 16 others	68/100
73rd	Akari Therapeutics 2005, New York City (United States), Public	Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system.	$2.43M	Foresite Capital, Deerfield & 7 others	56/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Akari Therapeutics's competitors? Click here to see the top ones

Akari Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Akari Therapeutics's geography:

Free

US Tech Semi Annual Funding Report

Edition: H1, 2026 (47 Pages)

View all reports related to Akari Therapeutics

Media has covered Akari Therapeutics for a total of 25 events in the last 1 year, 12 of them have been about company updates and 4 about people movement.